Business Wire20h
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...
Healio1d
Direct-to-consumer genetic testing for cancer predisposition can have ‘pitfalls’
Genomic cancer predisposition tests should be done with professional counseling, and the FDA should implement safeguards for ...
CURE3d
Test May Predict Likelihood of Bladder Cancer Upstaging
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers Will Be Presented at the 2025 ASCO GU Symposium.